Putnam, an Inizio Advisory company, developed a forward-looking early development program evaluation tool that identifies key inflection points, value drivers and risks for their client’s early oncology portfolio.
Read more about the client’s challenge, Putnam’s solution and the results.
Discover more about how we help to shape the future of oncology treatments here.
Our client was new to the complement system space and was preparing to launch an oral, first-in-class medication in a rare blood disease.
Read moreA top 10 pharma company wanted dermatologists to own the conversation on PsA, and become confident in diagnosing the disease.
Read moreA top 10 global pharma company wanted to challenge the status quo when it came to planning and prioritizing congresses.
Read more